VIFN CH0364749348

Report

Delayed Swiss Exchange - 05/18 11:30:15 am EDT
178.75	CHF		+0.42%

05/12	Update on the timeline for Vifor Pharma tender offer	BU
05/11	Australia shares slide as U.S. inflation data fuels slowdown woes	RE
04/29	VIFOR PHARMA AG : Ex-dividend day for final dividend	FA

Summary

Quotes 5-day view Delayed Quote.

Delayed Swiss Exchange

05/12/2022	05/13/2022	05/16/2022	05/17/2022	05/18/2022	Date
177.8(c)	178.2(c)	179(c)	178(c)	178.75(c)	Last
108 877	21 017	124 137	189 917	78 288	Volume
+1.98%	+0.22%	+0.45%	-0.56%	+0.42%	Change

More quotes

Estimated financial data (e)

Sales 2022	2 010 M 2 025 M 2 025 M
Net income 2022	315 M 317 M 317 M
Net cash position 2022	639 M 644 M 644 M
P/E ratio 2022	40,7x
Yield 2022	1,19%

Sales 2023	2 272 M 2 289 M 2 289 M
Net income 2023	376 M 379 M 379 M
Net cash position 2023	1 021 M 1 029 M 1 029 M
P/E ratio 2023	33,3x
Yield 2023	1,21%

Capitalization	11 551 M 11 636 M 11 636 M
EV / Sales 2022	5,43x
EV / Sales 2023	4,63x
Nbr of Employees	2 200
Free-Float	72,2%

More Financials

Company

Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject...

Sector

Pharmaceuticals

Calendar

08/04

Earnings Release

More about the company

Ratings of Vifor Pharma AG

Trading Rating :

Investor Rating :

ESG Refinitiv :

B+

More Ratings

All news about VIFOR PHARMA AG

05/12	Update on the timeline for Vifor Pharma tender offer	BU
05/11	Australia shares slide as U.S. inflation data fuels slowdown woes	RE
04/29	VIFOR PHARMA AG : Ex-dividend day for final dividend	FA
04/28	Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruri..	AQ
04/26	94th Vifor Pharma Group Annual General Meeting	BU
04/26	Vifor Pharma Ag Announces Board Changes	CI
04/26	Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022	CI
04/20	CSL Prices $4 Billion of Bonds in US Debt Market	MT
04/20	PAUL RAMSAY : KKR-led group offers record $14.8 billion bid for Australia's Ramsay Health	RE
04/04	Vifor Pharma Reports Long-Term Potassium Control from Phase 3b Trial for Veltassa	MT
04/04	DIAMOND TRIAL : Veltassa® enables patients to achieve long-term potassium control and opti..	BU
04/04	Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial	CI
03/30	VIFOR PHARMA AG(SWX : VIFN) dropped from Swiss Performance Index (Price Return)	CI
03/28	Australia's CSL Closes Public Tender Offer for Vifor Pharma	MT
03/28	Publication of definitive end result for Vifor Pharma tender offer	BU

More news

News in other languages on VIFOR PHARMA AG

05/16	BOLSA DE MADRID : Aterrizaje brusco en China
05/16	Atterrissage brutal en Chine
05/16	AVIS D'ANALYSTES DU JOUR : Michelin, Valeo, Ahold, SMA Solar, Sartorius, Orpea, Cosmo, Car..
05/12	La reprise de Vifor pourrait ne pas être bouclée d'ici fin juin
05/12	Abschluss der Vifor-Übernahme durch CSL verzögert sich

More news

Analyst Recommendations on VIFOR PHARMA AG

2021	Octavian Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation	MT
2021	Oddo BHF Lifts Price Target on Vifor Pharma, Downgrades Recommendation to Neutral	MT
2021	AlphaValue/Baader Europe Lifts Price Target on Vifor Pharma, Maintains Buy Recommendati..	MT

More recommendations

Provided by Scoopnest.com

Analysis

KKR-led group offers record $14.8 billion bid for Australia's Ramsay Health